2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium Channel

Related Products

PDF 3.33 MB

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Sodium Channel Isoform Specific Products:

Sodium Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-105084A
    Lubeluzole dihydrochloride
    		Inhibitor 99.00%
    Lubeluzole (dihydrochloride) is a neuroprotective agent which blockades neuronal voltage-gated sodium channels. Lubeluzole (dihydrochloride) also produces both tonic and block of cardiac sodium channels. Lubeluzole (dihydrochloride) is promising for research of antiarrhythmic agents.
    Lubeluzole dihydrochloride
  • HY-19366
    Nav1.7-IN-2
    		Inhibitor 99.81%
    Nav1.
    Nav1.7-IN-2
  • HY-119980S
    Fluphenazine-d8
    		Inhibitor 99.12%
    Fluphenazine-d8 is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
    Fluphenazine-d<sub>8</sub>
  • HY-B1798A
    Tocainide hydrochloride
    		Inhibitor 99.49%
    Tocainide hydrochloride is a sodium channel blocker, it blocks the sodium channels in the pain-producing foci in the nerve membranes. Tocainide hydrochloride is a primary amine analog of lidocaine, can be used for the treatment of tinnitus.
    Tocainide hydrochloride
  • HY-156596
    Aneratrigine
    		Inhibitor 99.60%
    Aneratrigine is a sodium channel protein type 9 subunit alpha blocker. Aneratrigine can be used for neuropathic pain diseases research.
    Aneratrigine
  • HY-B0185G
    Lidocaine (GMP)
    		Inhibitor
    Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.
    Lidocaine (GMP)
  • HY-123825
    GX-674
    		Antagonist
    GX-674 is a potent, state-dependent, isoform-selective voltage-gated sodium channel 1.7 (Nav1.7) antagonist with an IC50 of 0.1 nM at -40 mV.
    GX-674
  • HY-N1584AR
    Halofuginone hydrobromide (Standard)
    		Activator
    Halofuginone (hydrobromide) (Standard) is the analytical standard of Halofuginone (hydrobromide). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.
    Halofuginone hydrobromide (Standard)
  • HY-D2868
    DAPI
    		Inhibitor 98.01%
    DAPI (Compound 3) is an acid-sensing ion channel 3 (ASIC3) inhibitor. DAPI binds to ASIC3 and blocks the channel function. DAPI can be used in the study of chronic pain treatment.
    DAPI
  • HY-15736
    Sodium Channel inhibitor 1
    		Inhibitor 99.38%
    Sodium Channel inhibitor1, one of 3-Oxoisoindoline-1-carboxamides, is a novel and selective voltage-gated sodium channel for pain treatment.
    Sodium Channel inhibitor 1
  • HY-12533A
    Disopyramide phosphate
    		Inhibitor 99.85%
    Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action.
    Disopyramide phosphate
  • HY-128922S
    Dexamethasone palmitate-d31
    		Inhibitor 99.31%
    Dexamethasone palmitate-d31 is the deuterium labeled Dexamethasone palmitate(HY-128922).Dexamethasone palmitate (DXP) is a proagent of Dexamethasone (HY-14648). Dexamethasone palmitate can be used for the research of inflammation.
    Dexamethasone palmitate-d<sub>31</sub>
  • HY-B0122R
    Topiramate (Standard)
    		Inhibitor
    Topiramate (Standard) is the analytical standard of Topiramate. This product is intended for research and analytical applications. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate (Standard)
  • HY-108506R
    Licarbazepine (Standard)
    		Inhibitor
    Licarbazepine (Standard) is the analytical standard of Licarbazepine. This product is intended for research and analytical applications. Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects.
    Licarbazepine (Standard)
  • HY-P990898
    Amlenetug
    		99.85%
    HY-P990898 is an SNCA-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Amlenetug
  • HY-B1304
    (-)-Sparteine sulfate pentahydrate
    		Inhibitor
    (-)-Sparteine sulfate pentahydrate ((-)-Lupinidine sulfate pentahydrate) is a class 1a antiarrhythmic agent and a sodium channel blocker.
    (-)-Sparteine sulfate pentahydrate
  • HY-B0563S
    (Rac)-Ropivacaine-d7
    		99.60%
    (Rac)-Ropivacaine-d7 is the deuterium labeled (Rac)-Ropivacaine.
    (Rac)-Ropivacaine-d<sub>7</sub>
  • HY-N1584R
    Halofuginone (Standard)
    		Activator
    Halofuginone (Standard) is the analytical standard of Halofuginone. This product is intended for research and analytical applications. Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.
    Halofuginone (Standard)
  • HY-P990503
    Anti-SCN9a/Nav1.7 Antibody
    		Inhibitor
    Anti-SCN9a/Nav1.7 Antibody is a human antibody expressed in CHO, targeting SCN9a/Nav1.7. Anti-SCN9a/Nav1.7 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-SCN9a/Nav1.7 Antibody
  • HY-102998
    Nav1.7-IN-6
    		Inhibitor
    Nav1.7-IN-6 (example 346) is a Nav1.7 selective inhibitor, which is extracted from patent WO2015078374A1.
    Nav1.7-IN-6
Cat. No. Product Name / Synonyms Application Reactivity
Sodium Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.